Skip to content

Clinical trials

Brain Neoplasms trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Brain Neoplasms Country / region: China Clear all

164 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20081
20102
20113
20127
20131
20145
20157
201611
201710
20189
201910
202015
202112
202215
202314
202416
202510
202615

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status63
Recruiting41
Completed35
Active, not recruiting10
Not yet recruiting10
Terminated3
Enrolling by invitation1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Sun Yat-sen University18
Fudan University12
Beijing Tiantan Hospital7
Chinese Academy of Medical Sciences7
Cancer Institute and Hospital, Chinese Academy of Medical Sciences6
Zhejiang Cancer Hospital5
Betta Pharmaceuticals Co., Ltd.4
Guangdong Association of Clinical Trials3
Peking Union Medical College Hospital3
Second Affiliated Hospital, Zhejiang University, School of Medicine3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Brain Neoplasms164
Carcinoma, Non-Small-Cell Lung48
Breast Neoplasms18
Glioma15
Lung Neoplasms12
Meningeal Carcinomatosis8
Neoplasms8
Glioblastoma7
Central Nervous System Neoplasms4
Cerebrovascular Disorders4

Trials

Showing 26 to 50 of 164. Each trial links to its page on Pharma Observatory.

64 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.